Literature DB >> 20713677

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.

Sidonie Lambert-Niclot1, Gilles Peytavin, Claudine Duvivier, Catherine Poirot, Michèle Algarte-Genin, Sophie Pakianather, Jean-Luc Meynard, Marc-Antoine Valantin, Jean-Michel Molina, Philippe Flandre, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin.   

Abstract

HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono- or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA shedding was observed in patients (1 on monotherapy and 2 on triple therapy), although they had undetectable HIV-1 RNA in plasma. The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20713677      PMCID： PMC2976146          DOI： 10.1128/AAC.00725-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

2.  Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses.

Authors:  Erin Chambers; Diane M Wagrowski-Diehl; Ziling Lu; Jeffrey R Mazzeo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-01-03       Impact factor: 3.205

3.  Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation.

Authors:  Christophe Pasquier; Deborah Anderson; Corinne Andreutti-Zaugg; Rianne Baume-Berkenbosch; Florence Damond; Aviva Devaux; Yvon Englert; Julie Galimand; Carole Gilling-Smith; Odile Guist'hau; Lital Hollander; Marianne Leruez-Ville; Benoit Lesage; Anne Maillard; Anne-geneviève Marcelin; Marie-Paule Schmitt; Augusto Semprini; Maria Vourliotis; Chong Xu; Louis Bujan
Journal:  J Med Virol       Date:  2006-07       Impact factor: 2.327

4.  Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

Authors:  B M Sadler; C D Hanson; G E Chittick; W T Symonds; N S Roskell
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 6.  Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.

Authors:  Myron S Cohen; Cynthia Gay; Angela D M Kashuba; Sally Blower; Lynn Paxton
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

7.  Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

Authors:  Christine Katlama; Roberto Esposito; Jose M Gatell; Jean-Christophe Goffard; Beatriz Grinsztejn; Anton Pozniak; Jurgen Rockstroh; Albrecht Stoehr; Norbert Vetter; Patrick Yeni; Wim Parys; Tony Vangeneugden
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

8.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes.

Authors:  Louis Bujan; Myriam Daudin; Tomohiro Matsuda; Laurence Righi; Laurence Thauvin; Laetitia Berges; Jacques Izopet; Alain Berrebi; Patrice Massip; Christophe Pasquier
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

10.  Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

Authors:  Jade Ghosn; Marie-Laure Chaix; Gilles Peytavin; Elisabeth Rey; Jean-Louis Bresson; Cécile Goujard; Christine Katlama; Jean-Paul Viard; Jean-Marc Tréluyer; Christine Rouzioux
Journal:  AIDS       Date:  2004-09-24       Impact factor: 4.177
View more
  14 in total

Review 1.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Authors:  Minh P Lê; Marie-Laure Chaix; François Raffi; Sylvie Chevret; Sébastien Gallien; Christine Katlama; Pierre Delobel; Yazdan Yazdanpanah; Juliette Saillard; Jean-Michel Molina; Gilles Peytavin
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

3.  Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

Authors:  Cyril Clavel; Gilles Peytavin; Roland Tubiana; Cathia Soulié; Catherine Crenn-Hebert; Isabelle Heard; François Bissuel; Houria Ichou; Claudia Ferreira; Christine Katlama; Anne-Geneviève Marcelin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 4.  Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.

Authors:  Z Huang; A Tomitaka; A Raymond; M Nair
Journal:  Gene Ther       Date:  2017-06-01       Impact factor: 5.250

Review 5.  Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.

Authors:  Sachin Jain; Kenneth H Mayer
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

Review 6.  Antiretrovirals and safer conception for HIV-serodiscordant couples.

Authors:  Lynn T Matthews; Jennifer A Smit; Susan Cu-Uvin; Deborah Cohan
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

7.  Tissue-specific HIV-1 infection: why it matters.

Authors:  Maile Ay Karris; Davey M Smith
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

8.  Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs.

Authors:  Marina Moreau; Anna Le Tortorec; Claire Deleage; Charles Brown; Hélène Denis; Anne-Pascale Satie; Olivier Bourry; Nathalie Deureuddre-Bosquet; Pierre Roques; Roger Le Grand; Nathalie Dejucq-Rainsford
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

Review 9.  Darunavir: a review of its use in the management of HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 11.431

10.  Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting.

Authors:  José R Arribas; Manuela Doroana; Dan Turner; Linos Vandekerckhove; Adrian Streinu-Cercel
Journal:  AIDS Res Ther       Date:  2013-01-24       Impact factor: 2.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.